Company TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
15.21 USD -2.31% Intraday chart for TG Therapeutics, Inc. -0.26% -10.95%

Business Summary

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Number of employees: 264

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Treatments for B-cell Diseases
100.0 %
3 100.0 % 234 100.0 % +8,290.02%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
3 100.0 % 234 100.0 % +8,290.02%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 93-05-17
Director of Finance/CFO 42 11-12-28
Investor Relations Contact - 11-11-30
Corporate Officer/Principal - 18-06-03

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 58 93-05-17
Director/Board Member 77 12-02-29
Director/Board Member 59 14-12-14
Director/Board Member 60 12-11-08
Director/Board Member 57 15-03-31
Director/Board Member 57 20-04-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 154,462,081 140,404,745 ( 90.90 %) 41,309 ( 0.0267 %) 90.90 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.029 %
13,670,944 9.029 % 235 M $
13,074,929 8.635 % 225 M $
BlackRock Advisors LLC
6.507 %
9,852,600 6.507 % 170 M $
8,253,573 5.451 % 142 M $
Darwin Global Management Ltd.
2.673 %
4,046,598 2.673 % 70 M $
Pictet Asset Management Holding SA
2.236 %
3,385,245 2.236 % 58 M $
Wellington Management Co. LLP
2.074 %
3,139,764 2.074 % 54 M $
Geode Capital Management LLC
2.045 %
3,096,646 2.045 % 53 M $
Millennium Management LLC
1.934 %
2,928,788 1.934 % 50 M $
Opaleye Management, Inc.
1.463 %
2,215,000 1.463 % 38 M $

Company contact information

TG Therapeutics, Inc.

3020 Carrington Mill Boulevard Suite 475

27560, Morrisville

+212 554 4484

http://www.tgtherapeutics.com
address TG Therapeutics, Inc.(TGTX)